Evidence map›Paper›PMID 39168632›Full record

ArticleEpidemiology and infection2024

Surveillance of SARS-CoV-2 prevalence from repeated pooled testing: application to Swiss routine data.

Julien Riou, Erik Studer, Anna Fesser, Tobias Magnus Schuster, Nicola Low, Matthias Egger, Anthony Hauser

Abstract read
In one paragraph

Article in Epidemiology and infection, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Julien RiouInstitute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.ORCID 0000-0002-3808-2852
Erik StuderFederal Office of Public Health, Liebefeld, Switzerland.
Anna FesserFederal Office of Public Health, Liebefeld, Switzerland.
Tobias Magnus SchusterFederal Office of Public Health, Liebefeld, Switzerland.
Nicola LowInstitute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
Matthias EggerInstitute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
Anthony HauserInstitute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.

Funding

Bundesamt für Gesundheit 142006323Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung 189498
6 · The paper itself

Abstract

Surveillance of SARS-CoV-2 through reported positive RT-PCR tests is biased due to non-random testing. Prevalence estimation in population-based samples corrects for this bias. Within this context, the pooled testing design offers many advantages, but several challenges remain with regards to the analysis of such data. We developed a Bayesian model aimed at estimating the prevalence of infection from repeated pooled testing data while (i) correcting for test sensitivity; (ii) propagating the uncertainty in test sensitivity; and (iii) including correlation over time and space. We validated the model in simulated scenarios, showing that the model is reliable when the sample size is at least 500, the pool size below 20, and the true prevalence below 5%. We applied the model to 1.49 million pooled tests collected in Switzerland in 2021-2022 in schools, care centres, and workplaces. We identified similar dynamics in all three settings, with prevalence peaking at 4-5% during winter 2022. We also identified differences across regions. Prevalence estimates in schools were correlated with reported cases, hospitalizations, and deaths (coefficient 0.84 to 0.90). We conclude that in many practical situations, the pooled test design is a reliable and affordable alternative for the surveillance of SARS-CoV-2 and other viruses.

Indexed as

Bayes TheoremCOVID-19SARS-CoV-2COVID-19 TestingHumansPrevalenceSwitzerlandepidemicsSARS-CoV-2screening programmesurveillance

Identifiers

PMID39168632
PMCPMC11736450

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.